secwatch.observer — SEC 8-K summary
======================================

Issuer:     QUEST DIAGNOSTICS INC (DGX)
CIK:        0001022079
Form:       8-K
Filed at:   2022-07-21T23:59:59+00:00
Accession:  0001022079-22-000118
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Quest Diagnostics Q2 rev $2.45B (-3.8% YoY); raises FY22 adj EPS guidance to $9.55-$9.95
--------------------------------------------------------------------------------

- Q2 reported diluted EPS $1.96 (down 60.5% YoY); adjusted diluted EPS $2.36 (down 25.8% YoY).
- Base business revenue $2.10B (+2.9% YoY); COVID testing revenue $355M (-30.5% YoY).
- Raises FY22 guidance: net revenues $9.50B-$9.75B, adjusted EPS $9.55-$9.95 (prior $9.00-$9.50).
- CEO-elect Jim Davis cites base business growth and expanded COVID molecular testing share.
- Company supports SALSA legislation to fix PAMA clinical lab fee schedule cuts.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1022079/000102207922000118/0001022079-22-000118-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1022079/000102207922000118/dgx-20220721.htm
  HTML page:      https://secwatch.observer/filing/0001022079-22-000118

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer